Genfit shares, up 24% over one month, among the best performers of the SBF 120
The Lille-based biotech specialising in liver and metabolic diseases recovers at the close, in a Paris market trending lower. It ranks among the index's best performers after a decline that had placed it at the bottom of the rankings.
The stock closed at €10.42, up 1.96%, while the SBF 120 fell 0.82%.
Genfit ranks second in the index, behind Eutelsat, and is one of the few gainers in a gloomy session for the CAC 40 (-0.85%). This rebound only partially offsets the weekly decline (-1.88% over seven days), while the monthly gain remains 24.05%.
On the moving averages, the price is 1.04% below the MA20 (€10.53), but 3.07% above the MA50 (€10.11) and 1.26% above the MA200 (€10.29). The stock thus regains ground within the zone of the three averages, following a sharp rebound begun at the end of October.
Iqirvo royalties up 188% and financing secured beyond 2028
When it published its nine-month results on November 5, 2026, Genfit reported Iqirvo royalties up 188% over the period.
The company stated that its resources allow it to finance its activities beyond the end of 2028, while still awaiting a possible new commercial milestone payment. Risks cited on that occasion include dependence on Ipsen, which accounts for 99.7% of royalty revenues.
On the pipeline side, three Phase 2 trials are underway, with results expected in 2027. The stock is up 172.9% over one year, but has given up nearly 25% over three months.
Following the previous session, in which it lost ground, the support at €7.83 and the resistance at €11.46 define the reference trading range.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorPharmacie et biotechnologies›Biotechnologies
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 36,4 millions d'euros
Quarterly revenue: 36,4 millions d'euros
Revenue growth: -7,1 %
Guidance from the release
« conforte GENFIT dans son anticipation de la réception possible d'un nouveau paiement d'étape commercial » ; « permettent un financement des activités au-delà de fin 2028 »
Risks mentioned
Dépendance envers Ipsen pour la majorité des revenus (redevances sur ventes d'Iqirvo), qui représente 99,7% des revenus de redevances
Paiements d'étape commerciaux futurs soumis à conditions réglementaires et commerciales incertaines
Besoin de financement au-delà de 2028 dépendant de la croissance des ventes d'élafibranor et de l'adoption commerciale des technologies NIS™
Opportunities identified
Croissance des ventes d'Iqirvo auprès d'Ipsen (188% YoY sur redevances) avec pic de ventes révisé à 1 milliard d'euros
Medicare a approuvé le remboursement du test NASHnext® en août 2026, ouvrant un marché potentiel estimé à plus de 1,5 milliard de dollars à horizon 2033
Lancement de trois essais cliniques de Phase 2 (ACLF, CCA) avec résultats attendus en 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.